10-Q: Apyx Medical Reports Q1 2024 Results: Revenue Declines Amidst Economic Uncertainty

Apyx Medical's first quarter 2024 revenue decreased by 15.6% year-over-year, primarily due to a decline in domestic sales of Advanced Energy products.

Summary

• Apyx Medical Corporation reported a net loss of $7.59 million for the first quarter of 2024, compared to a net loss of $3.53 million for the same period in 2023.
• Total revenue for Q1 2024 was $10.24 million, a decrease of 15.6% from $12.14 million in Q1 2023.
• The Advanced Energy segment saw a 23.1% decrease in sales, while the OEM segment experienced a 13.8% increase.
• Domestic sales decreased by 21.3%, while international sales remained relatively flat, decreasing by 0.2%.
• Gross profit decreased by 21.4% to $5.9 million, with a gross margin of 58.1%, down from 62.4% in the prior year period.
• The company's cash and cash equivalents decreased to $37.28 million at the end of Q1 2024, compared to $43.65 million at the end of 2023.
• The company has a $7.5 million delayed draw loan available until December 31, 2024, contingent on achieving a minimum revenue target.
• The company is involved in several product liability lawsuits, with estimated losses ranging from $1.3 million to $1.95 million.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to decreased revenue, increased losses, and ongoing legal challenges. While there are some positive aspects, the overall financial performance and future uncertainties weigh heavily on the sentiment.

Positives

• OEM segment sales increased by 13.8% due to increased sales volume to Symmetry Surgical.
• International sales accounted for 31.9% of total revenue, up from 26.9% in the prior year period.
• The company remains in compliance with the financial covenants of the Perceptive Credit Agreement.
• Interest income increased due to higher average balances in money market funds and U.S. Treasury securities.

Negatives

• Total revenue decreased by 15.6% year-over-year.
• Advanced Energy segment sales decreased by 23.1%, driven by a decline in domestic sales.
• Gross profit decreased by 21.4% with a lower gross margin of 58.1%.
• The company reported a net loss of $7.59 million for the quarter.
• Cash and cash equivalents decreased by $6.37 million during the quarter.
• The company is facing product liability lawsuits with estimated losses between $1.3 million and $1.95 million.
• Interest expense increased significantly due to the Perceptive Credit Agreement.

Risks

• The company is experiencing economic uncertainty in the capital equipment market, particularly in the aesthetic space.
• The company faces ongoing product liability lawsuits, with potential for material adverse impacts on financial condition.
• The company has incurred recurring net losses and cash outflows from operations, and anticipates continued losses in the near term.
• The company may need to raise additional capital through equity or debt financing, which could result in dilution or increased debt service obligations.
• Failure to achieve minimum revenue targets could impact the availability of the delayed draw loan.
• The company's future financial performance could be adversely impacted by inflation.

Future Outlook

The company plans to continue funding operations through existing cash, product sales, and potentially additional equity or debt financing. They anticipate continued losses in the near term and may need to delay, limit, reduce, or terminate sales, marketing, and product development if additional capital is not available.

Management Comments

• Management estimates that our products have been sold in more than 60 countries.
• We continue to drive sales in our Advanced Energy business by increasing the adoption of our multifunction generator and utilization of our single-use handpieces in the U.S. cosmetic surgery market and fulfilling demand from distributors in our international markets.
• We strongly encourage investors to visit our website: www.apyxmedical.com to view the most current news and to review our filings with the Securities and Exchange Commission.

Industry Context

The decrease in sales, particularly in the Advanced Energy segment, reflects broader economic uncertainty in the capital equipment market, especially within the aesthetic space. This suggests that Apyx Medical is not immune to industry-wide challenges affecting medical device companies.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the decline in Apyx Medical's Advanced Energy sales contrasts with the growth seen in some other medical device sectors, particularly those focused on less capital-intensive products.
• The company's gross margin of 58.1% is lower than some established medical device companies, which often maintain margins above 60%.
• The increase in OEM sales is a positive sign, but the overall financial performance indicates that Apyx Medical is facing challenges in its core Advanced Energy business, which is a key differentiator for the company.
• Companies like InMode and Cutera, which also operate in the aesthetic device market, have reported varying results, highlighting the competitive and volatile nature of this sector. Apyx's results suggest it is facing more headwinds than some of its peers.

Legal Proceedings

• The company is involved in a number of legal actions relating to the use of their Helium Plasma technology.
• The company is in a dispute with one of its insurance carriers regarding the total level of coverage available.
• The company has recorded estimated losses of $1.45 million and $1.3 million related to product liability lawsuits.
• There is a reasonable possibility of additional losses related to these matters, but the company is unable to provide an estimate of the range of such additional loss at this time.

Related Party Transactions

• The company made purchases from its Chinese supplier, which is also a related party, of approximately $51,000 and $44,000 for the three months ended March 31, 2024 and 2023, respectively.
• Two relatives of Nikolay Shilev, Apyx Bulgaria's Managing Director, are considered related parties.

Stakeholder Impact

• Shareholders are negatively impacted by the decreased revenue, increased losses, and potential dilution from future capital raises.
• Employees may be impacted by potential cost-cutting measures if the company's financial situation does not improve.
• Customers may be impacted by potential delays or changes in product availability due to the company's financial challenges.
• Suppliers may be impacted by potential changes in purchase commitments or payment terms.
• Creditors may be impacted by the company's increased debt and potential need for additional financing.

Next Steps

• The company plans to continue to fund operations through existing cash, sales of products, and if necessary, additional equity and/or debt financing.
• The company will continue to monitor and address the ongoing product liability lawsuits.
• The company will continue to work on initiatives to combat inflation.

Key Dates

Keywords

Apyx Medical, Renuvion, J-Plasma, Advanced Energy, OEM, Helium Plasma Technology, Medical Devices, Quarterly Report, Financial Results, Product Liability, Revenue, Net Loss, Gross Profit